Real-World Faricimab nAMD Outcomes
Faricimab treatment for nAMD showed improved or stabilized visual acuity and reduced retina thickness in a large study. Patients extended injection intervals while maintaining disease control. Faricimab targets VEGF and angiopoietin-2, potentially offering greater efficacy and reduced systemic risks compared to anti-VEGF-only treatments.
Reference News
Real-World Faricimab nAMD Outcomes
Faricimab treatment for nAMD showed improved or stabilized visual acuity and reduced retina thickness in a large study. Patients extended injection intervals while maintaining disease control. Faricimab targets VEGF and angiopoietin-2, potentially offering greater efficacy and reduced systemic risks compared to anti-VEGF-only treatments.